Page contentsKey factsDecisionKey facts Active Substance Lacutamab Therapeutic area Oncology Decision number P/0483/2022 PIP number EMEA-003281-PIP01-22 Pharmaceutical form(s) Solution for injection/infusion Condition(s) / indication(s) Treatment of Cutaneous T-Cell Lymphoma Route(s) of administration Intravenous use Contact for public enquiries Innate Pharma SAE-mail: info@innate-pharma.frTel. +33 430303030 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 02/12/2022DecisionP/0483/2022: EMA decision of 2 December 2022 on the granting of a product specific waiver for lacutamab (EMEA-003281-PIP01-22)AdoptedReference Number: EMA/871506/2022 English (EN) (213.81 KB - PDF)First published: 13/11/2023ViewShare this page